<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48527">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01825928</url>
  </required_header>
  <id_info>
    <org_study_id>100000-068944</org_study_id>
    <nct_id>NCT01825928</nct_id>
  </id_info>
  <brief_title>An Study of Paliperidone Extended-Release Tablets in the Treatment of Methamphetamine Dependence</brief_title>
  <official_title>A Multiple-Center, Randomized, Double-Blind Study of Paliperidone Extended-Release Tablets for Treatment of Methamphetamine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wei Hao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <authority>China: National Natural Science Foundation</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Methamphetamine  substance use is common worldwide. No approved pharmacologic treatments for
      methamphetamine dependence exist. paliperidone are Second generation antipsychotics，and have
      effects of  blocking dopamine2(D2) and 5-hydroxytryptamine 2A(5-HT) receptors
      neurotransmitters.To determine whether mirtazapine would reduce methamphetamine use among
      methamphetamine addicts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods:A Multiple-Center, Randomized, Double-Blind.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>abstinent time of Methamphetamine addict</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>duration days of methamphetamine-negative urine test results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of people who assessed by Abnormal Involuntary Movement Scale ,Simpson-Angus Scale and Barnes akathisia Scale and at least one  scale score is greater than 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General severity of Methamphetamine addict</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change in score of Brief Symptom Inventory（BSA）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Irritability severity of Methamphetamine addict</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change in score of Irritability，Depression and Anxiety Scale （IDA）</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Methamphetamine Dependence</condition>
  <arm_group>
    <arm_group_label>paliperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paliperidone arm,6mg/pill,6-12mg/day.last12weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo group,6mg/pill,6-12mg/day non-forced titration method,last 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paliperidone</intervention_name>
    <description>Paliperidone  group,6mg/pill,6-12mg/day non-forced titration method,last 12weeks</description>
    <arm_group_label>paliperidone</arm_group_label>
    <other_name>Paliperidone Extended-Release Tablets</other_name>
    <other_name>Invega</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo group,6mg/pill,6-12mg/day non-forced titration method,last 12 weeks</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients,Diagnostic and Statistical Manual of Mental Disorders 4thed. (DSM-IV)
             criteria for Methamphetamine dependence.

          2. Must sign a Information consent form.

          3. Required to provide detailed address and phone number

        Exclusion Criteria:

          1. Serious organic disease.

          2. Suicide ideation or hurt others.

          3. Taking antipsychotic within two weeks before.

          4. drug allergy to  Risperidone or paliperidone.

          5. pregnancy and breastfeeding women.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Hao, MD., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gang Wang, doctor</last_name>
    <phone>18684667092</phone>
    <email>visa8752@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gang Wang, doctor</last_name>
      <phone>18684667092</phone>
      <email>visa8752@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Gang Wang, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 5, 2013</lastchanged_date>
  <firstreceived_date>March 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>Wei Hao</investigator_full_name>
    <investigator_title>The Second Xiangya Hospital of Cental South University</investigator_title>
  </responsible_party>
  <keyword>Methamphetamine-Associated Psychosis</keyword>
  <keyword>paliperidone</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methamphetamine</mesh_term>
    <mesh_term>9-hydroxy-risperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
